Neose, BioGeneriX Enter Protein Pact

Neose Technologies has signed an agreement giving BioGeneriX AG an option to license its GlycoPEGylation technology. The total potential value of the deal wasn't disclosed in a press release by Neose. The biopharmaceutical company did say, however, that it includes milestones worth up to $61.5 million and unspecified upfront payments and royalties. The agreement aims to use the Neose technology to develop a "long-acting, next generation version of a currently marketed therapeutic protein," according to Neose.

iWon

(http://money.iwon.com/jsp/nw/nwdt_rt.jsp?cat=USMARKET&src=704&feed=dji§ion=news&news_id=dji-00099820050128&date=20050128&alias=/alias/money/cm/nw)